163 related articles for article (PubMed ID: 23504149)
1. Inhibition of AGEs formation by natural products.
Nagai R; Shirakawa J; Ohno R; Moroishi N; Nagai M
Amino Acids; 2014 Feb; 46(2):261-6. PubMed ID: 23504149
[TBL] [Abstract][Full Text] [Related]
2. Lipid glycation and protein glycation in diabetes and atherosclerosis.
Miyazawa T; Nakagawa K; Shimasaki S; Nagai R
Amino Acids; 2012 Apr; 42(4):1163-70. PubMed ID: 20957396
[TBL] [Abstract][Full Text] [Related]
3. [Advanced glycosylation end products and chronic complications of diabetes mellitus].
Méndez JD
Gac Med Mex; 2003; 139(1):49-55. PubMed ID: 12666409
[TBL] [Abstract][Full Text] [Related]
4. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(6):1013-5. PubMed ID: 16146671
[TBL] [Abstract][Full Text] [Related]
5. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes.
Meerwaldt R; Links T; Zeebregts C; Tio R; Hillebrands JL; Smit A
Cardiovasc Diabetol; 2008 Oct; 7():29. PubMed ID: 18840258
[TBL] [Abstract][Full Text] [Related]
6. Astragalosides isolated from the root of astragalus radix inhibit the formation of advanced glycation end products.
Motomura K; Fujiwara Y; Kiyota N; Tsurushima K; Takeya M; Nohara T; Nagai R; Ikeda T
J Agric Food Chem; 2009 Sep; 57(17):7666-72. PubMed ID: 19681610
[TBL] [Abstract][Full Text] [Related]
7. Advanced glycation end-products and the progress of diabetic vascular complications.
Jakus V; Rietbrock N
Physiol Res; 2004; 53(2):131-42. PubMed ID: 15046548
[TBL] [Abstract][Full Text] [Related]
8. Advanced glycation end products in clinical nephrology.
Kalousová M; Zima T; Tesar V; Stípek S; Sulková S
Kidney Blood Press Res; 2004; 27(1):18-28. PubMed ID: 14679311
[TBL] [Abstract][Full Text] [Related]
9. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine.
Booth AA; Khalifah RG; Hudson BG
Biochem Biophys Res Commun; 1996 Mar; 220(1):113-9. PubMed ID: 8602828
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes.
Cameron NE; Gibson TM; Nangle MR; Cotter MA
Ann N Y Acad Sci; 2005 Jun; 1043():784-92. PubMed ID: 16037306
[TBL] [Abstract][Full Text] [Related]
11. Molecular strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end products.
Aldini G; Vistoli G; Stefek M; Chondrogianni N; Grune T; Sereikaite J; Sadowska-Bartosz I; Bartosz G
Free Radic Res; 2013 Aug; 47 Suppl 1():93-137. PubMed ID: 23560617
[TBL] [Abstract][Full Text] [Related]
12. Two new prenylflavonoids from Epimedii Herba and their inhibitory effects on advanced glycation end-products.
Nakashima K; Miyashita H; Yoshimitsu H; Fujiwara Y; Nagai R; Ikeda T
J Nat Med; 2016 Apr; 70(2):290-5. PubMed ID: 26758618
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes.
Gardiner TA; Anderson HR; Stitt AW
J Pathol; 2003 Oct; 201(2):328-33. PubMed ID: 14517851
[TBL] [Abstract][Full Text] [Related]
14. Naturally occurring inhibitors against the formation of advanced glycation end-products.
Peng X; Ma J; Chen F; Wang M
Food Funct; 2011 Jun; 2(6):289-301. PubMed ID: 21779567
[TBL] [Abstract][Full Text] [Related]
15. Oxidative stress in diabetes - circulating advanced glycation end products, lipid oxidation and vascular disease.
Dias IH; Griffiths HR
Ann Clin Biochem; 2014 Mar; 51(Pt 2):125-7. PubMed ID: 24146184
[No Abstract] [Full Text] [Related]
16. Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design.
Khalifah RG; Chen Y; Wassenberg JJ
Ann N Y Acad Sci; 2005 Jun; 1043():793-806. PubMed ID: 16037307
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic intervention in diseases with advanced glycation end products in their pathogenesis].
Zuwała-Jagiełło J
Pol Merkur Lekarski; 2009 Aug; 27(158):152-6. PubMed ID: 19856885
[TBL] [Abstract][Full Text] [Related]
18. Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients.
Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
Med Hypotheses; 2005; 64(6):1208-10. PubMed ID: 15823719
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats.
Stracke H; Hammes HP; Werkmann D; Mavrakis K; Bitsch I; Netzel M; Geyer J; Köpcke W; Sauerland C; Bretzel RG; Federlin KF
Exp Clin Endocrinol Diabetes; 2001; 109(6):330-6. PubMed ID: 11571671
[TBL] [Abstract][Full Text] [Related]
20. Advanced glycation end products in diabetic corneas.
Kaji Y; Usui T; Oshika T; Matsubara M; Yamashita H; Araie M; Murata T; Ishibashi T; Nagai R; Horiuchi S; Amano S
Invest Ophthalmol Vis Sci; 2000 Feb; 41(2):362-8. PubMed ID: 10670463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
